Suppr超能文献

一线匹配相关供者造血干细胞移植与获得性重型再生障碍性贫血的免疫抑制治疗比较。

First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.

机构信息

Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany.

出版信息

PLoS One. 2011 Apr 25;6(4):e18572. doi: 10.1371/journal.pone.0018572.

Abstract

INTRODUCTION

Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunosuppressive therapy may be offered as alternative. The aim was to compare the outcome of these patients in controlled trials.

METHODS

A systematic search was performed in the bibliographic databases MEDLINE, EMBASE, and The Cochrane Library. To show an overview of various outcomes by treatment group we conducted a meta-analysis on overall survival. We evaluated whether studies reported statistically significant factors for improved survival.

RESULTS

26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. We did not identify any RCTs. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies.

CONCLUSIONS

Young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies.

摘要

简介

获得性重型再生障碍性贫血(SAA)是一种罕见且进行性疾病,其特征为造血干细胞的免疫介导功能障碍。如果有 HLA 匹配的相关供体,则移植这些细胞是一线治疗选择。否则可以选择一线免疫抑制治疗。目的是比较这些患者在对照试验中的结果。

方法

在 MEDLINE、EMBASE 和 The Cochrane Library 等文献数据库中进行了系统检索。为了通过治疗组展示各种结局的概述,我们对总生存率进行了 meta 分析。我们评估了研究是否报告了统计学上改善生存的显著因素。

结果

共确定了 26 项非随机对照试验(1970 年至 2001 年期间纳入了 7955 名患者)。我们没有发现任何 RCT。除了 4 项研究外,其余研究的偏倚风险都很高。HSCT 组中,年轻年龄和最近的治疗年份被确定为改善生存的因素。IST 组中,高龄、非极重型再生障碍性贫血 SAA 和抗淋巴细胞球蛋白联合环孢素 A 是改善生存的因素。在 19 项研究(4855 名患者)中,汇总统计数据足以进行 meta 分析。由于存在很大的异质性,因此无法得出合并估计值。不良事件的报告不一致,且在研究之间差异很大。

结论

年轻年龄和最近的治疗年份是移植组中改善生存的因素。高龄、非极重型再生障碍性贫血 SAA 和抗淋巴细胞球蛋白联合环孢素 A 是免疫抑制组中改善生存的因素。非随机对照研究的异质性很大,无法得出合并估计值。不良事件的报告不一致,且在研究之间差异很大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2d3/3081818/477a23a6c2f7/pone.0018572.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验